AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05476874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Puncture
Description: An about 0.5-cm paraumbilical incision made to allow introduction of a splitable trocar. The trocar is pierced through the abdominal wall into the abdominal cavity. Pull out the puncture cone, and adjust the trocar towards the pelvis. The distal catheter tip is inserted into the peritoneal cavity through the puncture cannula. Then the splitable puncture cannula is split apart and removed. The skin incision requires only one stitch.
Study NCT06454500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: A 48 hour expiration on orders placed for indwelling urinary catheters.
Study NCT06028685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupoint stimulation
Description: The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.
Study NCT06028685 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupoint stimulation(placebo)
Description: The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
Study NCT04550988 — intervention group
Intervention type: OTHER
Intervention: feasibility study
Description: The aim of this study is to evaluate the possibility of establishing a patient-based ultrasound monitoring of the knee (representing a target joint accessible with any hand) with a handheld device.
Study NCT04570436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 600 mg
Description: participants will receive an oral dose of gabapentin 600 mg
Study NCT04570436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1200 mg
Description: participants will receive an oral dose of gabapentin 1200 mg
Study NCT04570436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 1800 mg
Description: participants will receive an oral dose of gabapentin 1800 mg
Study NCT04570436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazepam 20 mg
Description: participants will receive an oral dose of 20 mg dose of diazepam
Study NCT04570436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants will receive an oral dose of placebo
Study NCT06429566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray low dose group、high dose group
Description: Administrated oral spray. Each subject will take oral GB001 recombinant peptide spray 4 times a day, 4 sprays each time, no more than 29 times，The dosage of the group is 0.108mg/spray for low dose group and 0.216mg/spray for high dose group.
Study NCT06429566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray placebo
Description: Administrated oral spray.Each subject will take oral GB001 recombinant peptide spray placebo 4 times a day, 4 sprays each time, no more than 29 times
Study NCT06497452 — intervention group
Intervention type: DRUG
Intervention: Glofitamab
Description: Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin human
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide Acetate
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study NCT05313828 — intervention group
Intervention type: DRUG
Intervention: Acyclovir
Description: acyclovir 4 times /day
Study NCT05313828 — intervention group
Intervention type: DRUG
Intervention: Tobramycin
Description: tobramycin 4 times /day
Study NCT05313828 — intervention group
Intervention type: DRUG
Intervention: Fluorometholone
Description: Fluorometholone 4 times/ day
Study NCT05313828 — intervention group
Intervention type: DRUG
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate 4 times/day
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Synthetic pure glucocorticoid used to induce temporary insulin resistance, administered orally as seven 1-mg doses over 72 hours.
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [6,6-2H2] D-glucose
Description: Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)
Study NCT05618938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado's approach
Description: Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~1. Rest position of the tongue~2. Control of TMJ rotation~3. Rhythmic stabilization technique~4. Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks
Study NCT05618938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kraus exercises
Description: Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing~4. Tongue up and wiggle~5. Strengthening~6. Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [6,6-2H2] D-glucose
Description: Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% D-glucose (aq)
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)
Study NCT04954456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31901
Description: QLS31901 is a bispecific antibody specifically targeting PD-L1 and TGF-β.In part 1,the QLS31901 will be administered in sequential cohorts on day 1 of every 21-day cycle (3 weeks) via IV infusion.In part 2,the QLS31901 will be administered in parallel cohorts(selected dose and dosing frequency ) on day 1 of every 2week or every 3week via IV infusion
Study NCT06126354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% D-glucose (aq)
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOOST Plus
Description: Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOOST Plus
Description: Nutritional supplement will be administered to provide three standardized mixed meals on the day before the pancreatic clamp.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harvard Apparatus PHD ULTRA CP syringe pump
Description: Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvard Apparatus PHD ULTRA CP syringe pump
Description: Device: Harvard Apparatus PHD ULTRA CP syringe pump Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Description: Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Description: Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.~(Non-investigational)
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl, aq), variable rate (as needed)
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline (0.9% NaCl, aq), variable rate (as needed)
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
Study NCT06126354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin (5%, aq), 0.4 g per 100 mL of infusion (0.4% (w/v) in insulin and OCT/GCG/GH bags)
Study NCT06165783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercises and Ultrasound
Description: describe the rationale and methodology for evaluating the effect of using therapeutic exercises and ultrasound in the rehabilitation of partially injured hamstring muscles
Study NCT04049630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 1 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study NCT04049630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 1,5 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study NCT04049630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV 2,5 mg/kg
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study NCT04049630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.
Study NCT04049630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 tablets of placebo will be administrated to the participants.
Study NCT04332796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorhexidine scrub
Description: Chorhexidine scrub was given to patients for 4 weeks
Study NCT04332796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZnO-NPs socks
Description: ZnO-NPs socks was given to patients for 4 weeks
Study NCT04332796 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of chorhexidine scrub and ZnO-NPs socks
Description: Combination of chorhexidine scrub and ZnO-NPs socks was given to patients for 4 weeks
Study NCT05426434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
Study NCT05426434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine (SP)
Description: SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
Study NCT05426434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine (SP)
Description: SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
Study NCT06382012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: Fosaprepitant 150mg IV administered over 15 minutes
Study NCT06382012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 mg
Description: Ondansetron 4mg IV administered over 15 minutes
Study NCT04685902 — intervention group
Intervention type: DEVICE
Intervention: One-way speaking valve
Description: One-way speaking valve is a small device that attaches to the tracheostomy tube, to allows tracheostomy patient to breathe in through his or her trach tube. After the inhalation, the speaking valve closes. Air is breathed out (exhaled) up through the vocal cords, then through the mouth and nose.
Study NCT05280301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sous Vide Device (SVD)
Description: A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer and the SVD every 2 minutes. At the end of the 30 minute treatment, the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
Study NCT05215340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT05928013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurothesiometer
Description: The 'gold standard' device for Vibration Perception Threshold testing
Study NCT05928013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NERVE
Description: The experimental device for Vibration Perception Threshold testing developed by the project team
Study NCT05215340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT05215340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study NCT06273098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Health Education
Description: This will be a combination of bladder health education and awareness events, additional resources such as a water station to support healthy bladder behaviors, and tailored changes to classroom bathroom policies that are TBD (e.g. mobile technology bathroom passes).
Study NCT06524466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab
Description: SBRT: SBRT will be performed within 2-4 weeks after enrollment. The total radiation dose will be 24 Gy, delivered in 3 fractions on alternate days, to be completed within one week.~Lenvatinib: 8mg/day, begin immediately after enrollment. Lenvatinib should be discontinued one week before surgery.~Pucotenlimab: 200mg，3-week interval between cycles, begin immediately after enrollment, a total of four cycles of Puco treatment must be completed before surgery.~Surgical resection will be performed within 10-16 weeks after the completion of SBRT.
Study NCT04893486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: QTORIN 3.9 % Sirolimus Topical Gel
Study NCT04893486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle comparator
Description: Vehicle comparator topical gel
Study NCT05330221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAL2
Description: Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
Study NCT05330221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHARM-PAL2
Description: All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention.
Study NCT05050201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepio
Description: Digital CBT application for insomnia
Study NCT04914611 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05944523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spina Plan Block
Description: Preemptive erector spina plan block and postoperative erector spina plan block were applied to patients undergoing thoracotomy. The effect of the time of application on intraoperative opioid consumption was compared with the Nociception Level Index pain monitor.
Study NCT05460494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELOAD-C
Description: RELOAD-C is a web-based platform that centralizes 6 brief videos of our MCP expert (Dr. Applebaum) discussing sources of meaning, links to virtual group meetings facilitated by a social worker trained in MCP to promote discussion of MCP concepts, and written content providing guidance on homework and exercises referenced in the MCP videos
Study NCT06682663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Streaming Exercise
Description: Participants try to achieve 150 minutes of moderate-vigorous training per week. The exercise program includes live streaming exercise by trained health professionals, including pregnancy-specific exercises, with professional pregnancy trainers to provide guidance and support when needed.
Study NCT06489470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strokectomy/Necrosectomy
Description: After obtaining CT-/MRT-perfusion, the infarcted area (e.g. infarct core) of malignant MCA-infarction is localized. By using the neuronavigation, surgical resection of necrotic tissue is performed in a non-eloquent area until the space occupying effect is released. At the end of the surgery, the bone flap is reinserted and fixated.
Study NCT05152641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117, 4mg
Description: BGE-117, 4mg Capsules
Study NCT05152641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets
Study NCT05152641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulfate
Description: Ferrous Sulfate, 325mg Tablets
Study NCT05152641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo to BGE-117 Capsules